We’re proud to provide a platform for influential voices in academia/industry. Check out our roster of speakers for the upcoming conference below, and read through their bios to get a better sense of what you can expect from their sessions.

If you’re interested in learning more, feel free to reach out.

Charles Yang genetech.jfif



SM Pharmaceutics

Charles Yang is an Executive Director and the department head of the Small Molecule Pharmaceutics (SMP) in Genentech Research and Early Development (gRED). SMP consists of multiple technical functions, including Discovery Pharmaceutics, Solid State Chemistry Characterization, BioPharmaceutics, Formulation/Drug Delivery, and GMP Operations.  SMP is responsible for designing and delivering pre-/clinical formulations for gRED chemically synthesized compounds, including small molecules, ASOs, CIDEs, macrocycles, and CKPs.

Charles holds a PhD in Materials Science and Engineering from Drexel University. Prior to joining Genentech in May-2015, Charles worked in Pharm Research / Merck (West Point, PA) and in Drug Product Technology / Amgen (Thousand Oaks, CA).  Noteworthy, Charles served as Amgen Drug Product Lead to transfer Corlanor® (ivabradine 5mg/7.5mg) into US under unprecedented timeline, including six primary stability batches at the commercial scale, authored NDA DP sections, executed PPQ campaign, and received FDA approval in April-2015.

Igor-Gonda Respidex.png


Respidex LLC

I have a passion for the the development of therapies for unmet or poorly met medical needs. My research has been primarily in severe respiratory diseases and their treatment by inhaled medications.  I enjoy working with the critical stakeholders in this process - the patients, their relatives and caregivers, multidisciplinary R&D teams and regulators. In addition to my involvement in research all the way from the bench to executive positions in industry, I have taught pharmaceutical sciences and have been fortunate to work with many talented young scientists who studied and collaborated with me as graduate students, postdoctoral fellows and research associates in England, Australia and USA.



Triastek Inc.

Innovation Center

Yu Zheng, Ph.D. is the manager of innovation center at Triastek, Inc. He received BS in Pharmacy and MS in Chemical Biology from Peking University in 2005 and 2008, respectively. Dr. Zheng obtained his Ph.D. in Chemical and Pharmaceutical Sciences from the University of the Pacific in 2013. Prior to his industry career, he was a postdoctoral research fellow in Dr. Xiaoling Li’s and Dr. Bhaskara Jasti’s research lab and a research assistant professor at the University of the Pacific. After joined Triastek, Dr. Zheng’s work primarily focuses on applying 3D printing technology in the development of novel drug delivery systems.



Catalent Cell and Gene Therapy

Anushree Herwadkar is a Senior Scientist (Formulation Development) at Catalent Cell and Gene Therapy. She has her Ph.D. in Pharmaceutical Sciences from Mercer University, Atlanta GA. Thereafter she has been working in the pharmaceutical industry in the area of Formulation Development. Prior to joining Catalent, Anushree held positions in the Formulation Development groups at Novavax Inc. and Teva Pharmaceutical Industries Ltd.

Zhixin Lu.JPG


University of Pittsburgh
School of Medicine, Division of Infectious Diseases